To uncover the mechanisms underlying dCK silencing in our drug-resistant sublines, and considering previous reports of genomic deletions of the dCK locus in AML patients’ specimens and tumor cell lines10,34, we evaluated the genomic dCK levels in these sublines. The gene discussed is DCK; the disease is acute myeloid leukemia.